Biopharma | May 13, 2026
Agilent and Veeda collaborate to strengthen regulatory-ready biopharma analytics
The two companies will establish a joint Center of Excellence (CoE) in Bengaluru
The two companies will establish a joint Center of Excellence (CoE) in Bengaluru
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
The newly formed team is led by Tomabu Adjobimey, an immunologist known for his work in host-pathogen interactions and immune modulation
These tests deliver results in 10–15 minutes at a cost of Rs 100–Rs 150, compared to conventional diagnostics which cost up to Rs 15,000
The event marks a significant push into South Korea’s rapidly expanding bio-health ecosystem
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
This event will bring together global stakeholders to explore India’s growing capabilities in pharma and biopharma innovation, research, and manufacturing
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
Subscribe To Our Newsletter & Stay Updated
